Skin Brightening activity of 10 percent Vitamin C Serum

A Clinical Study to Evaluate the Skin Brightening activity of 10% Vitamin C Serum - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2026/05/110796

Enrollment

Registered

2026-05-21

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: 10% Vitamin C Serum: Quantity2 mg/sq.cm Route of administration: Topical Frequency: Once Duration: 24 hour Intervention2: Test Product: 10% Vitamin C Serum: Test Product:

Eligibility

Inclusion criteria

Inclusion criteria: 1. Individual should have ITA angle in the range of 28 t0 40, 41 to 55, and greater than 56 2. Individuals free of any dermatological or systemic disorder which would interfere with the results, at the discretion of the investigator. 3. Individuals who have completed a preliminary medical history evaluation. 4. Individuals who have read, understood and signed an informed consent document relating to the specific study to which they are subscribing. 5. Individuals with no known abnormal response to sunlight.

Exclusion criteria

Exclusion criteria: 1.Subjects who are pregnant, breast feeding, or planning to become pregnant during the study 2.Volunteers with skin conditions such as eczema, psoriasis, etc 3.Have any evidence of systematic cancer, squamous cell carcinoma, basal cell carcinoma in the last 5 years, or any other confounding skin condition. 4.Have open sore or open lesions in the treatment area 5.Have any condition that, in the opinion of the investigator, would confound the safety and efficacy assessments of the product. 6.Have participated in any interventional clinical trial in the previous 30 days. 7.Have a known sensitivity to any of the constituents of the test product including sensitivities to any of the constituents. 8.Have used, are using, or are planning to use immunosuppressive or immunomodulatory medications (i.e., biologics), including corticosteroids. Have a history of alcohol or illegal drug/ substance abuse or suspected alcohol or illegal drug/substance abuse in the past 2 years.

Design outcomes

Primary

Measure	Time frame
1. change in Skin Pigmentation 2. change in Skin Discoloration 3. Dermat evaluationTimepoint: At Day 0, Day 14 & Day 28	—

Secondary

Measure	Time frame
1. HD ImagingTimepoint: At Day0, Day28	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results